Source - LSE Regulatory
RNS Number : 9197S
Evgen Pharma PLC
22 March 2021
 

Evgen Pharma Plc

("Evgen" or "the Company")

 

Appointment of Chief Business Officer

 

Evgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer, inflammation and acute respiratory distress syndrome, announces that Helen Kuhlman PhD will be joining the Company as Chief Business Officer effective from 1 April 2021.

 

Dr Kuhlman has over 20 years' experience in government funding and equity investment together with scientific and business roles in public and private R&D-based biotechnology companies. She joins Evgen from the Development Bank of Wales where she was responsible for equity investment in technology companies and for managing investments in the bank's portfolio companies. Prior to that Helen was Vice-President of Corporate Development at Chronos Therapeutics Ltd and was previously at Innovate UK where she created and delivered the £180m Biomedical Catalyst competitive grant scheme funded by the UK government. Dr Kuhlman holds a PhD in physiology and pharmacology from the University of Leicester, UK.

 

Dr Huw Jones CEO of Evgen commented: "We are delighted to appoint Helen to a key senior role within the Company as we increase our focus on potential partnering activities for SFX-01. Helen will also have a key role within the team in providing a commercial focus on our indication selection, horizon scanning and competitor intelligence activities."

 

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

Enquiries:

 

Evgen Pharma plc www.evgen.com 

via Walbrook 

Barry Clare, Chairman 


Richard Moulson, CFO 




finnCap www.finncap.com 

+44 (0)20 7220 0500

Geoff Nash / Teddy Whiley (Corporate Finance) 


Alice Lane (ECM) 




Walbrook PR 

+44 (0)20 7933 87870 or evgen@walbrookpr.com

Paul McManus / Anna Dunphy 

+44 (0)7980 541 893 / +44 (0)7876 741 001 

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

 

Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.

 

The Company commenced operations in January 2008 and has its headquarters at Alderley Park, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For research on the Company, please visit: http://evgen.com/investors/analyst-coverage/

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSFSFIUEFSEID
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts

Evgen Pharma PLC (EVG)

0p (0.00%)
delayed 16:57PM